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ABSTRACT
Prolonged exposure to topotecan in in vitro and in vivo
experiments has yielded the highest antitumor efficacy. An
oral formulation of topotecan with a bioavailability of 32–
44% in humans enables convenient prolonged administra-
tion. Pharmacokinetic/pharmacodynamic relationships
from four Phase I studies with different schedules of admin-
istration of oral topotecan in 99 adult patients with malig-
nant solid tumors refractory to standard forms of chemo-
therapy were compared. Topotecan was administered as
follows: (a) once daily (o.d.) for 5 days every 21 days (29
patients); (b) o.d. for 10 days every 21 days (19 patients); (c)
twice daily (b.i.d.) for 10 days every 21 days (20 patients);
and (d) b.i.d. for 21 days every 28 days (31 patients). Phar-
macokinetic analysis was performed in 55 patients using a
validated high-performance liquid chromatographic assay
and noncompartmental pharmacokinetic methods. Totals of
109, 48, 64, and 59 courses were given, respectively. Dose-
limiting toxicity consisted of granulocytopenia for the o.d. 3
5-day dosage, a combination of myelosuppression and diar-
rhea in both of the 10-day schedules, and only diarrhea in
the 21-day schedule. Pharmacokinetics revealed a substan-
tial variation of the area under curve (AUC) of topotecan
lactone in all of the dose schedules with a mean intrapatient
variation of 25.4 6 31.0% (o.d. 3 5), 34.5 6 25.0% (o.d. 3
10), 96.5 6 70.1% (b.i.d. 3 10), and 59.5 6 51.0% (b.i.d. 3
21). Significant correlations were observed between myelo-
toxicity parameters and AUC(t) day 1 and AUC(t) per
course of topotecan lactone. In all of the studies, similar
sigmoidal relationships could be established between AUC(t)
per course and the percentage decrease of WBCs. At max-
imum-tolerated dose level, no significant difference in
AUC(t) per course was found [AUC(t) per course was
107.4 6 33.7 ngzh/ml (o.d. 3 5), 145.3 6 23.8 ngzh/ml (o.d. 3
10), 100.0 6 41.5 ngzh/ml (b.i.d. 3 10), and 164.9 6 92.2
ngzh/ml (b.i.d. 3 21), respectively.] For oral topotecan, the
schedule rather than the AUC(t)-per-course seemed to be
related to the type of toxicity. Prolonged oral administration
resulted in intestinal side effects as a dose-limiting toxicity,
and short-term administration resulted in granulocytopenia.
On the basis of this pharmacokinetic study, no schedule
preference could be expressed, but based on patient conven-
ience, administration once daily for 5 days could be favored.
INTRODUCTION
Topotecan, 9-dimethylaminomethyl-10-hydroxycamptoth-
ecin, is a water-soluble semisynthetic analogue of camptothecin
(1). Like camptothecin, topotecan is a specific inhibitor of
topoisomerase I. Topotecan administered daily by 30-min infu-
sion on 5 subsequent days every 3 weeks results in brief my-
elosuppression as the most important side effect (2–5). Antitu-
mor activity was reported in patients with small cell lung cancer
(6) and in pretreated patients with ovarian cancer (7–9). Re-
cently topotecan was registered in Europe and the United States
for the latter indication. Cytotoxicity of topoisomerase I inhib-
itors is more specific to the S-phase of the cell cycle, in which
double-strand breaks occur (10–12).
Preclinical in vitro and in vivo studies indicate that pro-
longed exposure to low-dose topoisomerase I inhibitors is the
most efficacious (13–18). The feasibility of the concept of
prolonged exposure to topotecan in humans was initially re-
ported by Hochster et al. (19) in a Phase I study using a 21-day
continuous infusion. Myelosuppression was the DLT2, and re-
markable antitumor activity was seen. Infusion, especially con-
tinuous infusion, is relatively patient-inconvenient. Recent stud-
ies in humans reported a 32–44% bioavailability of the i.v.
formulation of topotecan when given p.o. (20, 21). Oral admin-
istration would be a more simple and perhaps a more convenient
method to achieve prolonged exposure.
We performed four Phase I and pharmacological studies
with different schedules of oral administration of topotecan in
adult patients. The present analysis was performed to seeReceived 1/30/98; revised 8/20/98; accepted 8/28/98.
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whether, from a pharmacokinetic/pharmacodynamic point of
view, there was a preference for a particular schedule to be taken
forward for further development.
PATIENTS AND METHODS
Patient Selection. Patients with a histologically con-
firmed diagnosis of malignant solid tumor refractory to standard
forms of therapy were eligible. Eligibility criteria included: (a)
age $18 years; (b) WHO performance status #2; (c) an esti-
mated life expectancy of $12 weeks; (d) no previous anticancer
therapy $4 weeks (6 weeks for nitroso-ureas or mitomycin C);
and (e) adequate hematopoetic (WBCs $4 3 109/liter and
platelets $100 3 109/liter), hepatic (bilirubin within normal
limits, AST,ALT, and/or alkaline phosphatase #2 3 normal),
and renal function (serum creatinine #133 mmol/liter (2.0 mg/
dl). Specific exclusion criteria included: (a) active peptic ulcer
or any gastrointestinal condition that could alter absorption or
motility; (b) the taking of H2-antagonists or proton pump inhib-
itors. All of the patients gave written informed consent.
Treatment and Dose Escalation. Oral administration of
topotecan was studied in four Phase I studies: (a) b.i.d. for 21
days every 28 days; (b) once or b.i.d. for 10 days every 21 days;
and (c) o.d. for 5 days every 21 days. The 21-day administration
was studied based on the 21-day continuous i.v. administration
(19, 22, 23). In view of the relatively short half-life of topotecan,
the twice-daily dosing was given. Dose levels studied were 0.15,
0.3, 0.4, 0.5, and 0.6 mg/m2 b.i.d., which resulted in total daily
doses of 0.3, 0.6, 0.8, 1.0, and 1.2 mg/m2), respectively. The
10-day schedules were studied because of severe diarrhea oc-
curring in the third week of the 21-day administration of oral
topotecan and the finding that topoisomerase I down-regulation
was optimal after 10–14 days with continuous infusion of
topotecan (19, 23, 24). Dose levels studied with the 10-day
administration were 0.5, 0.6, 0.7, and 0.8 mg/m2 b.i.d., and 1.0,
1.4, and 1.6 mg/m2)/day o.d. The reduction from two to one
administration/day was intended to reduce gastrointestinal tox-
icities. A daily 3 5 dose o.d. every 21 days was based on the
daily 3 5 i.v. administration, with dose levels 1.2, 1.8, 2.3, and
2.7 mg/m2/day.
Dose escalations were based on the toxicity seen at the
prior dose level. If no toxicity was seen in the prior dose,
#100% dose escalation was allowed. However, if toxicity was
seen, a dose escalation of 25–50% was prescribed. The MTD
was defined as one dose level below the dose that induced
DLTs, which were defined as CTC grade IV hematological
toxicity and/or nonhematological toxicity $CTC grade III dur-
ing the first course in more than 2 of 6 patients. Intrapatient dose
escalation was not allowed.
Treatment Source and Formulation. Topotecan was
supplied as capsules containing topotecan hydrochloride, equiv-
alent to either 0.25, 0.50, or 1.0 mg of the anhydrous free base
(SmithKline Beecham). Capsules had to be stored at between
2°C and 8°C. Capsules were taken with a glass of water in the
morning on an empty stomach with a 2-h period of fasting. With
b.i.d. administration of topotecan, the second dose was taken
with an interval of 12 h with a glass of water at least 10 min
before meals, preferably on an empty stomach. Patients were
treated as outpatients.
Treatment Assessment. Before therapy and weekly dur-
ing therapy, evaluations were performed including history,
physical examination, toxicity assessment according to the CTC
criteria, and serum chemistries (25). Complete blood counts
were determined twice weekly. Tumor measurements were per-
formed after every two courses and evaluated according to the
WHO criteria for response (26). Patients were taken off of the
protocol in the case of disease progression.
Pharmacokinetics. For pharmacokinetic analysis, whole
blood samples (2.8 ml) in heparinized tubes were collected
during the first course, before dosing, and 15, 30, and 45 min
and 1, 1.5, 2.5, 3.5, 4.5, 8.5, and 12 h after the administration of
the drug on day 1 and on day 4 (o.d. 3 5), or day 8 (3 10 and 3
21 schedules). For the twice-daily dosing schedules, pharmaco-
kinetic samples were taken after the morning dose. The samples
were immediately processed and analyzed according to a
method described previously (27).
AUCs of topotecan lactone and hydroxy-acid were calcu-
lated by noncompartmental analysis (linear-logarithmic trape-
zoidal method). Because a .20% extrapolation was needed to
calculate the total AUC of topotecan lactone in most cases of the
b.i.d. 3 21 and b.i.d. 3 10 administration, pharmacokinetic-
pharmacodynamic analysis was carried out with AUC(t) in all
studies. AUC(t) was calculated up to the last measured time
point “t”. In all of the patients, samples were obtained up to 12 h
after drug intake. The terminal half-life (T1/2) was calculated as
ln2/k, where ln2 is logarithm and k is the elimination rate
constant (h-1). In the studies with a o.d. administration of topo-
tecan, no steady-state situation will be reached because of the
T1/2 of 3.5–4.0 h. To compare the four schedules of adminis-
tration, we chose AUC per course as a reliable measure for dose
intensity. The AUC(t) per course was calculated by multiplying
the AUC(t) day 1 with the number of doses per course. The
AUC(t) day 1 and AUC(t) per course were fitted to the observed
percentage decrease in WBCs using the sigmoidal Emax model
(28). For all calculations, the Siphar software package release
4.0 (Siphar SIMED, Cedex, Creteil, France) was used. Spear-
man rank correlation coefficients were calculated between
AUC(t) day 1 and AUC(t) per course and the percentage of
decrease of WBCs, granulocytes, and platelets.
Two-way ANOVA was used to compare AUC(t) per
course for the different schedules at MTD dose level. ANOVA
was used for analysis on difference in myelotoxicity, diarrhea,
maximal concentration day 1, and intrapatient variation. Intrapa-
tient variation was calculated as follows (day 4/8, either day 4 or
day 8):
AUC day 1 2 AUC day 4/8
AUC day 1 3 100%
The duration of exposure to topoisomerase I inhibitors
seems important for antitumor effects. In vitro experiments with
continuous exposure of topotecan were performed with a min-
imum concentration of 100 ng/ml (16), and steady-state plasma
concentrations were 0.62 and 4.4 ng/ml, respectively, in studies
in humans with 21 day continuous infusion (19, 22). An arbi-
trary threshold plasma concentration of .1 ng/ml was chosen to
study the differences in duration of exposure in the schedules
used. Duration of time of topotecan .1 ng/ml per course was
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calculated from the duration measured on day 1 multiplied by
the number of doses per course.
RESULTS
A total of 99 eligible patients were entered into the studies,
of whom 96 were evaluable for toxicity.Because of technical
problems during the shipment of the blood samples from the
patients from San Antonio, reliable pharmacokinetic data could
not be obtained from these patients. Pharmacokinetic analysis
could be performed in 55 patients treated at the Rotterdam
Cancer Institute. The patient characteristics are given in Table 1.
The median WHO performance status of patients was: 0 (range,
0–2). The majority of patients received prior chemotherapy;
minimally or extensively pretreated patients were balanced in
the four schedules studied.
Hematological Toxicity. The occurrence of CTC grade
III–IV leucocytopenia and granulocytopenia with the various
schedules is listed in Table 2. They were observed in 11.9% and
Table 2 Toxicities in patients treated with oral topotecan
Schedule and dose levelsa
No. of
patients
No. of
courses
Leucocytes Granulocytes Platelets
Nausea
III
Vomiting Diarrhea
IIIb IV III IV III IV III IV III IV
Once daily
3 5 days
All 29 109 9 4 15 8 3 5 5 1 3 0 1
MTD 8 15 2 3 1 3 0 2 2 0 2c 0 0
3 10 days
All 19 48 1 2 0 2 1 3 1 1 0 5 0
MTD 9 (1)d 18 (1)d 0 2 0 2 0 2 1 1 0 3 0
Twice daily
3 10 days
All 18 64 0 3 0 3 1 1 3 0 2 2 3
MTD 6 15 0 1 0 1 0 1 1 0 0 1 1
3 21 days
All 30 59 4 2 1 2 1 2 0 0 0 1 6
MTD 8 18 2 2 0 2 0 2 0 0 0 0 2
a All, patients studied at all dose levels; MTD, patients studied at MTD dose level.
b CTC grades. Toxicity per course.
c In both of these patients, a relationship to topotecan is possible.
d The number in parentheses is the number of patients who were also studied at this dose level but who had been treated previously at a higher
dose level.
Table 1 Patient characteristics oral topotecan
o.d. b.i.d.
3 5 days 3 10 days 3 10 days 3 21 days
Number of patients
Entered 29 19 20 31
Evaluable 29 19 18 30
Age, median (range) 53 (27–72) 53 (19–85) 55 (41–69) 55 (33–73)
WHO performance, median (range) 0 (0–I) 0 (0–I) 0 (0–I) 0 (0–II)
Tumor types
Colorectal 10 4 11 12
Ovarian 3 4 3 3
NSCLCa 2 2 2 2
SCLC 2 3 1 0
Breast 2 0 0 2
Hepatocellular 2 1 0 0
Miscellaneous 8 5 3 12
Prior therapy
Chemotherapy 19 11 14 14
Radiotherapy 0 1 1 2
Both 3 5 1 14
None 7 2 3 1
Immunotherapy 0 0 1 0
No. of courses 109 48 64 59
Median (range) 2 (1–14) 2 (1–7) 2 (1–17) 2 (1–10)
a NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.
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21.1%, respectively, of courses at the daily 3 5 administration,
6.2% and 4.2%, respectively, of courses with o.d. 3 10, both
4.6% of courses with b.i.d. 3 10, and 10.2% and 5.1% of
courses for b.i.d. 3 21, respectively.
Granulocytopenia was significantly (P , 0.001) more fre-
quent in the daily 3 5 administration as compared with the other
schedules; this was true for leucocytopenia also.
At MTD, granulocytopenia was more frequent with the
daily 3 5 administration with a median duration of 6.5 days
(range, 2–12 days), and it was never complicated by fever. At
MTD, granulocytopenia was relatively mild in the b.i.d. 3 21
and o.d. 3 10 schedules. Granulocytopenia was complicated by
fever in one patient treated at MTD with the b.i.d. 3 10
administration. CTC grade III–IV thrombocytopenia was noted
in 8 (7.3%), 4 (8.3%), 2 (3.1%), and 3 (5.1%) courses of the o.d.
3 5, o.d. 3 10, b.i.d. 3 10, and b.i.d. 3 21 administration
(N.S.), most often in conjunction with CTC grade III–IV leu-
cocytopenia.
Nonhematological Toxicity. Diarrhea CTC grade III–IV
was seen in 1.0% of courses o.d. 3 5, 10.5% of courses o.d. 3
10, 7.8% of courses at b.i.d. 3 10, and 11.9% of courses with
b.i.d. 3 21 (P 5 0.03; Table 2). Diarrhea was the only DLT at
0.6 mg/m2 b.i.d for the 21-day administration. DLT consisted of
a combination of myelosuppression and diarrhea at 0.8 mg/m2
b.i.d. 3 10 and 1.6 mg/m2) o.d. 3 10. Granulocytopenia was
DLT at 2.7 mg/m2) o.d. 3 5.
At MTD, no CTC grade III–IV diarrhea occurred with the
daily 3 5 administration. CTC grade IV diarrhea was seen in
two of eight patients treated at MTD with the 21-day schedule.
For the different schedules of administration, MTDs were 0.5
mg/m2 b.i.d. 3 21, 0.7 mg/m2 b.i.d. 3 10, 1.4 mg/m2/day 3 10,
and 2.3 mg/m2/day 3 5.
Pharmacokinetics and Dynamics. The AUC(t) of topo-
tecan lactone was consistently higher on day 4 (o.d. 3 5) and
day 8 (10- and 21-day schedules) compared with day 1. Signif-
icant correlations were found between AUC(t) day 1 and day 4/8
(Table 3). In the b.i.d. 3 10 schedule AUC(t), day 8 was
significantly higher compared with day 1 (P , 0.05). Thus,
limited cumulation of topotecan occurred in this schedule. Bear-
ing this in mind, the mean intrapatient variation of AUC(t)
topotecan lactone was 25.4% 6 31.0% (o.d. 3 5; n 5 22),
34.5% 6 25.0% (o.d. 3 10; n 5 10), 96.5% 6 70.1% (b.i.d. 3
10; n 5 10) and 59.5 6 51.0% (b.i.d. 3 21; n 5 13), respec-
tively. Intrapatient variation appeared lower in the o.d. dose
schedules because of a more limited increase of AUC(t) topo-
tecan lactone as compared with the b.i.d. schedules. Interpatient
variation (% coefficient of variation) was 43.1% (o.d. 3 5),
40.1% (o.d. 3 10), 73.4% (b.i.d. 3 10) and 59.1% (b.i.d. 3 21).
Table 3 Correlations coefficients (R): pharmacokinetics and dynamics
Correlation o.d. 3 5 days (R) o.d. 3 10 days (R) b.i.d. 3 10 days (R) b.i.d. 3 21 days (R)
AUC(t) day 1 vs. AUC(t) day 4/8 0.81 0.76 0.74 0.95
P 5 0.001 P 5 0.01 P 5 0.02 P 5 0.001
Cmax vs. % decrease granulocytes 0.55 N.S.a N.S. 0.72
P 5 0.02 P 5 0.02
Topotecan lactone . 1 ng/ml per course
vs. % decrease leucocytes
0.44 0.74 0.99 Not reliable
P 5 0.04 P 5 0.02 P 5 0.0001
AUC(t) day 1 topotecan vs. % decrease
leucocytes
0.76 0.61 0.69 0.66
P 5 0.001 P 5 0.06 P 5 0.03 P 5 0.03
AUC(t) day 1 vs. % decrease platelets 0.60 0.83 0.78 Not reliable
P 5 0.004 P 5 0.01 P 5 0.03
a N.S., not significant.
Table 4 Pharmacokinetics after oral administration of topotecan in patients treated at MTD (Median (range)
Schedule
MTD AUC(t) topotecan
Cmax topotecan,
day 1 (ng/ml)No. of patients Dose (mg/m2/day) Day 1 (ng z h/ml) Per course Per wk
o.d. 3 5 days qa 3 wk 6 2.3
Median 19.6 97.9 32.6 8.4
Range 13.1–33.0 65.7–165.0 21.9–55.0 4.6–11.1
SD 6.7 33.7 11.2 2.2
o.d. 3 10 days q 3 wk 3 1.4
Median 13.2 131.7 43.9 3.3
Range 13.1–17.3 131.4–172.8 43.8–57.6 3.0–6.8
SD 2.4 23.8 7.9 3.3
b.i.d. 3 10 days q 3 wk 4 1.4
Median 5.6 111.1 37.2 1.3
Range 2.2–6.6 44.20–132.8 14.7–44.3 0.7–2.4
SD 2.1 41.5 13.8 0.7
b.i.d. 3 21 days q 4 wk 4 1.0
Median 4.1 172.6 43.1 1.6
Range 1.6–5.9 68.5–246.1 17.1–61.5 0.9–2.4
SD 2.2 92.2 23.1 0.6
a q, every.
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Cmax was correlated to the percentage of decrease of gran-
ulocytes for o.d. 3 5 and for b.i.d. 3 21 (Table 3). Cmax did not
correlate with other myelotoxicity parameters. Time-point of
maximal concentration and half-life were of similar magnitude
for all of the four dose schedules (N.S.).
The AUC per course at MTD was not significantly differ-
ent between the four schedules of oral administration (Table 4).
The resulting AUC per course at MTD was 107.4 6 33.7
ngzh/ml for o.d. 3 5, 145.3 6 23.8 ngzh/ml for o.d. 3 10,
100.0 6 41.5 ngzh/ml for b.i.d. 3 10, and 164.9 6 92.2 ngzh/ml
for b.i.d. 3 21 (N.S.) (Table 4). The AUC per week at the MTD
dose level, a measure for dose intensity, was not significantly
different between the 4 schedules studied (Table 4).
Calculating AUC per course at MTD from AUC(t) day 4/8
resulted in an AUC per course of 124.8 6 50.2 ngzh/ml (o.d. 3
5), 217.2 6 75.6 ngzh/ml (o.d. 3 10), 164.1 6 70.0 ngzh/ml
(b.i.d. 3 10), and 229.4 6 79.5 ngzh/ml (b.i.d. 3 21), respec-
tively (N.S.).
A duration of time of topotecan lactone .1 ng/ml per
course was lowest in the o.d. 3 5 administration with a mean
duration of 20.1 6 7.9 h/course. Duration of topotecan .1
ng/ml per course was 26.5 6 13.6 h (o.d. 3 10), 47.9 6 49.2 h
(b.i.d. 3 10), and 44.6 6 12.2 h (b.i.d. 3 21), respectively.
Duration of time of topotecan lactone .1 ng/ml per course was
significantly lower (P 5 0.006) for the 5 day o.d. schedule
compared with the 10-day and 21-day b.i.d. schedules.
The correlation between topotecan lactone .1 ng/ml per
course with the percentage of decrease of leukocytes was low
for o.d. 3 5 but higher in the 10-day schedules (Table 3). The
correlation for the 21-day schedule could not be calculated
reliably.
The correlation between the AUC(t) day 1 of topotecan and
the percentage of decrease of leukocytes is significant in the o.d.
3 5, b.i.d. 3 10, and b.i.d. 3 21 schedules of administration.
The correlation between AUC(t) day 1 topotecan and percentage
decrease of leukocytes showed a same trend for the o.d. 3 10
administration. The relationship between the AUC(t) day 1 of
topotecan lactone and the percentage of decrease of leukocytes
could be fitted best using a sigmoidal Emax model (Fig. 1).
A significant correlation between the AUC(t) of topotecan
lactone and the percentage decrease of platelets was observed in
the 10-day dose schedules and in the 5-day schedule (Table 3).
Thus, significant correlations with myelotoxicity parameters are
found with all schedules. When plotting AUC day 1 and day 4/8
per course against the percentage decrease of leukocytes, all of
the sigmoidal curves showed a similar pattern (Fig. 2, a and b).
DISCUSSION
A 21-day continuous infusion of topotecan in patients with
solid tumors was well tolerated, and antitumor effects were seen
(19, 22). Continuous infusion is inconvenient and sometimes
leads to complications of the central venous catheters (19, 22).
Oral administration of topotecan may perhaps be more conven-
ient in patients and was considered worthwhile testing in view
of a bioavailability of 32–44% of the i.v. formulation when
given p.o. (20, 21).
For both oral and i.v. topotecan administered on 5 consec-
utive days every 3 weeks, myelosuppression was dose limiting.
No clinically important diarrhea was seen in the daily 3 5-day
administration. In contrast, for the b.i.d. 3 21-day administra-
tion of oral topotecan, uncontrollable diarrhea was the single
Fig. 1 Sigmoidal relationship between AUC day 1 and percentage
decrease of leukocytes (all studies).
Fig. 2 a, sigmoidal relationship between AUC (day 1) per course and
percentage decrease of leukocytes (all studies). b, sigmoidal relationship
between AUC (day 4/8) per course and percentage decrease of leuko-
cytes (all studies).
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dose-limiting side effect, whereas the dose-limiting side effect
was myelotoxicity in studies on 21-day continuous infusion. The
latter studies did not report severe diarrhea. Diarrhea is a well-
known side effect of camptothecin and its derivatives.
CPT-11 administered i.v. can cause acute onset diarrhea or
delayed onset diarrhea starting around day 5. CPT-11 delayed-
onset diarrhea is controllable by vigorous administration of
loperamide (29). Oral administration of camptothecin for 21
days every 28 days and 9-nitro-camptothecin for 5 days/week
resulted in severe diarrhea in 40 and 33% of patients, respec-
tively (30, 31). Local intestinal effects of camptothecin and its
derivatives seem to be responsible for diarrhea (32). Diarrhea
that was induced by oral topotecan was always self-limiting but
did not respond to loperamide administration.
The data from our studies suggest that local intestinal
exposure is an inducing factor for the observed diarrhea, al-
though the exact mechanism of topotecan-induced diarrhea is
unknown. DLT consisted of a combination of both myelotoxic-
ity and diarrhea in the studies with 10-day administration of oral
topotecan. Thus, with the oral administration of topotecan, the
toxicity profile seemed to change gradually from granulocyto-
penia to diarrhea when administration was prolonged.
Neutropenia is the major side effect of daily 3 5 i.v.
topotecan, with the nadir of granulocytes being reported be-
tween days 8 and 15 (2–5). The continuous i.v. administration of
topotecan for 21 days every 28 days showed a granulocyte nadir
on day 18 (range, 12–28) (19). Granulocyte nadirs of the
daily 3 5 administration of oral or i.v. topotecan were similar,
as were those of myelotoxicity of the o.d. 3 10 (days 12 and 16)
and b.i.d. 3 10 (days 8–14) oral schedules. In none of the
schedules of oral administration of topotecan was myelotoxicity
cumulative. These findings are consistent with previous reports
on daily 3 5 administration of topotecan. Neutropenia had a
median duration of 6.5 days (range, 2–12 days) and was un-
complicated in the daily 3 5 administration of oral topotecan. In
contrast, cumulative myelotoxicity requiring dose reductions was
seen in schedules with 21 days of continuous infusion (19, 22).
With the 21 days of oral administration, plasma concentra-
tions of topotecan lactone .1 ng/ml never lasted for more than
3 h per administration. In contrast, 20 (91%) of the 22 patients
analyzed in the daily 3 5 study had a plasma concentration of
topotecan lactone .1 ng/ml lasting for more than 3 h, as did 5
patients (50%) on o.d. 3 10 days and 1 patient (10%) with b.i.d.
administration. The duration of topotecan lactone plasma-con-
centration .1 ng/ml per course however was highest with the
21-day schedule and lowest for o.d. 3 5 days. Because granu-
locytopenia was significantly more frequent in the o.d. 3 5-day
administration, myelotoxicity seems to be related to the plasma
concentration per dose administered rather than the duration of
exposure to .1 ng/ml topotecan per course.
Compared with oral administration o.d. 3 5 days, AUC(t)
of topotecan lactone is substantially higher with i.v. administra-
tion, and neutropenia is more pronounced (33–37). Furthermore,
mild myelotoxicity was the major side effect of 21 days’ con-
tinuous infusion of topotecan with achieved mean steady-state
topotecan lactone plasma-concentrations varying from 0.62 6
0.17 (22) to 4.4 6 0.99 ng/ml (19). Together with the finding of
mild myelotoxicity in the b.i.d. 3 21-day oral administration,
with a low mean Cmax of 1.40 6 0.74, myelotoxicity may be
related to the topotecan plasma level rather than to the time of
duration of exposure to the drug. Systemic exposure from low-
dose prolonged administration of camptothecin and its deriva-
tives 9-amino-camptothecin and 9-nitro-camptothecin showed
more efficacy in tumor reduction in studies with human xe-
nografts (14, 15), and these schedules were tolerated better than
the i.v. schedules with higher doses. Apparently myelotoxicity
can be circumvented by prolonged administration of low-dose
topoisomerase I inhibitors.
Interpatient and—especially—intrapatient variation
seemed to be most limited with o.d. 3 5-day oral administration.
As in previous studies with i.v. topotecan, a significant corre-
lation of the AUC(t) day-1 topotecan and percentage decrease of
leukocytes was found with all schedules. When AUC(t) per
course is plotted against the percentage of decrease of leuko-
cytes, similar sigmoidal curves are found. At MTD, AUC per
course and AUC per week were similar for all oral schedules.
Thus, AUC per week, as a measure of dose intensity, was not
significantly different in the four schedules studied.
For oral administration of topotecan, as yet only preclinical
studies on prolonged administration show remarkable antitumor
effects with less toxicity as compared with shorter schedules.
The four Phase I studies presented here are the first studies with
oral administration of topotecan in patients with solid tumors
and were not designed to confirm the above information ob-
tained in animal models. Oral administration of topotecan, es-
pecially in the o.d. 3 5-day schedule, is safe, with uncompli-
cated granulocytopenia as the main side effect, limited
intrapatient variation, and similar dose intensity as compared
with the other schedules of oral administration. Phase II studies
with the daily 3 5-day schedule will show whether this schedule
is an active regimen. The 10-day and especially the 21-day
administrations can result in unpredictable and sometimes clin-
ically severe uncontrollable diarrhea. For these reasons and
because a 5-day schedule is more convenient to patients, the o.d.
3 5-day oral administration of topotecan is preferred for future
studies.
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